AchillesLatest News

Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours

19/11/2020

– Financing includes leading US-based life science investors OrbiMed and Boxer Capital of Tavistock Group Stevenage, UK 19 November 2020 –...

Read More +

Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer

11/11/2020

– Related patent recently granted and equivalent applications pending in multiple countries Stevenage, UK 11 November 2020 – Achilles Therapeutics Limited (“Achilles”),...

Read More +

Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer

07/10/2020

Stevenage, UK 7 October 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel...

Read More +

Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer

07/07/2020

Stevenage, UK 7 July 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that...

Read More +

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

23/06/2020

Stevenage, UK 23 June 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that...

Read More +

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens

29/05/2020

Stevenage, UK 29 May 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that...

Read More +

Achilles Therapeutics to present at Jefferies Virtual Healthcare Conference

28/05/2020

Stevenage, UK 28 May, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel...

Read More +

Achilles Therapeutics announces formation of Scientific Advisory Board

13/05/2020

– World-leading experts in oncology, immunology and R&D will advise the Company as it advances pipeline of pioneering cancer therapies –...

Read More +

Achilles Therapeutics to present a manufacturing update at the virtual 2020 AACR Annual Meeting

22/04/2020

Stevenage, UK 22 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel...

Read More +

Sign up foremail alerts

We'll keep you connected to the latest news about Achilles

By providing your name and email address, you consent to Achilles Therapeutics Limited using these details to send you emails relating to the latest news and updates about Achilles. You can withdraw your consent at any time by emailing dataprotection@achillestx.com, or clicking on the unsubscribe link at the end of any email you receive from us. For more information, including your rights relating to your personal data, please see our Privacy Policy